Vector Innovation Fund: erster $300 million pandemic protection fund

Kate­gorie: Deals
Foto: Das Ziel des VIF: Schutz vor Pandemien
3. Februar 2021

Luxem­burg — Vector Inno­va­tion Fund GP S.à.r.l. (VIF) has now launched an expected $300 million pandemic protec­tion sub-fund 1. This first sub-fund aims to invest in tech­nolo­gies for pandemic protec­tion and future health­care, aiding and support­ing preci­sion medi­cine, highly advanced point of care and AI tech­nolo­gies to support the global econ­omy, sustain­able health­care, and life longevity. This first sub-fund’s objec­tive is to target commit­ments totalling $300m due to a strong deal flow, with an expected first close of $120m and a final close expected within 19 months.

The General Part­ners have an excel­lent track record in indus­try, health­care, tech­nol­ogy and invest­ment, with 21 exits and a total value creation of $2.4billion, includ­ing two success­ful IPOs.

VIF is a Reserved Alter­na­tive Invest­ment Fund based in Luxem­bourg has just been incor­po­rated under the laws of the Grand Duchy of Luxem­bourg as a corpo­rate part­ner­ship limited by shares (société en comman­dite par actions) qual­i­fy­ing as an invest­ment company with vari­able capi­tal — reserved alter­na­tive invest­ment fund (société d’investissement à capi­tal vari­able – fonds d’investissement alter­natif réservé) under the RAIF Law.

VIF has been set up as an umbrella struc­ture with sub-fund Vector Inno­va­tion Fund – Pandemic Protec­tion Fund 1 at incor­po­ra­tion date. The General Part­ner might, at its discre­tion, launch addi­tional sub-funds (which may be open-ended or close-ended) each of which is repre­sented by one or more Classes of Shares. The fund qual­i­fies as an AIF within the mean­ing of the AIFM Law.

Each sub-fund shall consti­tute a distinct and segre­gated part of the assets and liabil­i­ties of VIF’s umbrella struc­ture.

Economic fore­cast­ers say fall­out from COVID-19 is driving huge invest­ment within AI and Nanotech­nol­ogy as health­care invest­ment is expected to grow at a rate of nearly 50% extra a year towards a market set to be worth $1.333 tril­lion by 2027, accord­ing to Prece­dence Research 2020.

The Pandemic Protec­tion sub-fund 1 plans to invest in sophis­ti­cated biotech and nanotech­nol­­ogy-based diag­nos­tics, biomark­ers, vaccines, novel ther­a­pies, highly targeted nanomed­i­cines, and AI, allow­ing us to move to a more sustain­able, digi­tised, decen­tralised and democ­ra­tised point-of-care envi­ron­ment. The world cannot afford another pandemic, the ongo­ing impact of long Covid symp­toms will have a profound effect on health­care provi­sion for the next five to ten years. The world of invest­ment, indus­try and govern­ments are gear­ing up to be better prepared and are fund­ing future the proof tech­nolo­gies for global health.

These dynamic invest­ments will help to poten­tially free up our economies and future-proof us from infec­tious diseases as well as develop solu­tions to antibi­otic resis­tance, another global health­care chal­lenge that only tech­nol­ogy can solve.

VIF, repre­sented by its manag­ing general part­ner Vector Inno­va­tion GP, has also appointed Fuchs Asset Manage­ment S.A., led by CEO Timo­the Fuchs. Fuchs Asset Manage­ment S.A. is a public limited liabil­ity company based in Luxem­bourg, as the qual­i­fied Fund Manager (AIFM) governed under Luxem­bourg law for reserved alter­na­tive invest­ment funds under RAIF Law 2016.

The appointed invest­ment advi­sor for the fund is Enabling Tech Invest­ment Advi­sors S.À R.L. who is also based and incor­po­rated in Luxem­bourg under Luxem­bourg law. VIF’s depos­i­tory bank is Banque de Luxem­bourg. Other inter­na­tional service providers include Mait­land, Ashurst, The World Nano Foun­da­tion and World Science Aid.

The fund has brought together some of the world’s lead­ing figures in biomed­i­cine, advanced diag­nos­tics, nano biomark­ers, telemed­i­cine, AI and machine learn­ing to accel­er­ate these trans­for­ma­tional tech­nolo­gies into the markets, backed by sophis­ti­cated, UHNW and insti­tu­tional investors creat­ing poten­tially one of the most dynamic inter­na­tional invest­ment struc­tures.

VIF’s fund invest­ment strat­egy looks to deliver 25–30% esti­mated gross IRR, 4x MOIC over the life of the fund with an esti­mate of 10–12 diver­si­fied invest­ments per sub-fund.

Each prospect company seek­ing invest­ment from VIF must demon­strate to our invest­ment advi­sors, our global advi­sory board, invest­ment commit­tee and fund managers, their abil­ity to commer­cialise highly disrup­tive tech­nol­ogy glob­ally. For this, VIF uses its unique propri­etary rating system for strat­egy imple­men­ta­tion, using world-class bench­mark model­ling for tech­nol­ogy and health­care invest­ment.

The Fund’s Enabling Tech­nol­ogy Invest­ment Advi­sors and global advi­sory board are inter­na­tional lead­ers in these fields of exper­tise. This has been demon­strated via previ­ous start ups that have gone on to become ‘unicorns’, as well as our team’s wider expe­ri­ence with large conglom­er­ates in terms of advis­ing and support­ing them on strat­egy, scal­ing or commer­cial­is­ing disrup­tive inno­va­tions in inter­na­tional markets.

One inter­na­tional invest­ment plat­form is a Pandemic Protec­tion alter­na­tive invest­ment fund oper­ated by Vector Inno­va­tion Fund in Luxem­bourg focused on limit­ing the effect of long form Covid-19, insu­lat­ing the world against the impact of future pandemics, whilst minimis­ing any impact on the global econ­omy and health­care provi­sion and prepared­ness. As well as this, the fund is commit­ted to enhanc­ing the devel­op­ment and preva­lence of nanotech­nol­ogy in health­care.

The Vector Inno­va­tion Fund is a Reserved Alter­na­tive Invest­ment Fund (RAIF) special­is­ing in support for tech­nol­ogy compa­nies able to trans­form global markets, notably in global health­care, sustain­abil­ity and longevity. These trans­for­ma­tional tech­nolo­gies come from the nanotech­nol­ogy, biotech, AI and machine learn­ing, medical devices, ther­a­pies and digi­tal health sectors.

‍The Vector Inno­va­tion Fund (VIF) is a semi-regu­lated alter­na­tive invest­ment fund based in Luxem­bourg and offers all the bene­fits a sophis­ti­cated or accred­ited inter­na­tional investor would require and has several sub-funds: Pandemic Protec­tion Fund, Enabling Tech­nolo­gies Fund, Future Health­care Fund.

The VIF was incor­po­rated on 30th Novem­ber 2020 for its first sub fund for Pandemic Protec­tion Fund and Future Health­care.

Newsletter abonnieren

Hier erfahren Sie von den neuesten Transaktionen, Börsengängen, Private Equity-Deals und Venture Capital-Investments, wer einen neuen Fonds eingesammelt hat, wie es um die Buy & Build-Aktivitäten steht.

Get in touch

Kontaktieren Sie uns!
fyb [at]